Volume 150, Issue 3, Pages (September 2018)

Slides:

Advertisements

Similar presentations

Nicoletta Colombo, Martin Gore

Advertisements

Volume 144, Issue 1, Pages (January 2017)

Oncol Res Treat 2016;39: DOI: /

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Volume 149, Issue 2, Pages (May 2018)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Table 2. Progression-Free Survival

Volume 141, Issue 2, Pages (May 2016)

Volume 135, Issue 1, Pages (October 2014)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Volume 148, Issue 1, Pages (January 2018)

The development and use of vascular targeted therapy in ovarian cancer

Volume 145, Issue 2, Pages (May 2017)

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma Hiroaki Takahashi,

Volume 146, Issue 1, Pages (July 2017)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

Kaplan-Meier curves for overall survival (OS) probability.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

The origins of multidisciplinary cancer care

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 153, Issue 1, Pages (April 2019)

Volume 152, Issue 1, Pages (January 2019)

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Volume 152, Issue 1, Pages (January 2019)

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 82, Issue 9, Pages (November 2012)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Fig. 1. Kaplan-Meier curves for PFS and OS

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 150, Issue 3, Pages 471-477 (September 2018) Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study Ignace Vergote, Roger von Moos, Luis Manso, Els Van Nieuwenhuysen, Nicole Concin, Cristiana Sessa Gynecologic Oncology Volume 150, Issue 3, Pages 471-477 (September 2018) DOI: 10.1016/j.ygyno.2018.07.018 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 The NovoTTF-100 L(O) System is a portable medical device delivering alternating electric fields to the pelvis/abdomen using 4 transducer arrays. The System can be portable when operated using a battery, allowing normal daily activities. The model presented is an actor and not a patient. Gynecologic Oncology 2018 150, 471-477DOI: (10.1016/j.ygyno.2018.07.018) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Progression free survival results of the INNOVATE Study Kaplan-Mayer curves for the Intent-to-treat population. The median PFS was 8.9 months (95% CI 4.7, NA). Gynecologic Oncology 2018 150, 471-477DOI: (10.1016/j.ygyno.2018.07.018) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Overall survival results of the INNOVATE Study. Kaplan-Mayer curves for the Intent-to-treat population the median OS was not reached (95% CI 10.2, NA). Gynecologic Oncology 2018 150, 471-477DOI: (10.1016/j.ygyno.2018.07.018) Copyright © 2018 The Authors Terms and Conditions